After her second birthday, my daughter began displaying mild symptoms of what I feared was a seizure disorder. As a genetic counselor, I was acutely aware of what another parent may have deemed trivial. I caught an episode on video and a few days later found myself in the waiting room of the best pediatric neurologist in Manhattan. The children in this room were a stark reminder of the news I could potentially face. I stared at the fish tank fighting back tears until the nurse called my daughter’s name.
The doctor reassured me everything was “probably fine.” The only way to confirm was to admit her to the hospital and monitor brain activity for 24-48 hours. We checked in, and my daughter got to choose the color of the EEG wires. She chose “rainbow,” and as they glued the multiple nodes to her scalp, I distracted her with games.
My daughter shared a hospital room with a nine-year-old girl being similarly monitored. This girl could not speak, and it was clear that my two-year-old was more advanced in milestones. In conversation, her mom informed me that her daughter had an undiagnosed rare genetic disease. I listened as she unloaded the story of her child’s history, which included multiple visits to physicians, routine EEG monitoring, occupational therapy, daily medications and special schooling. As I waited to learn more about my own daughter’s situation, I briefly shared another mother’s deep sense of uncertainty.
When I read the recent New York Times article about DNA testing, I was similarly struck by the shared parental agony of waiting. Dr. Gibbs captures the extent to which parents search for answers: “[driving] across the whole country looking for that one neurologist who can help, or scrubbing the whole house with Lysol because they think it might be an allergy.” In the case of the Sukin family, the wait finally led to a diagnosis and subsequent plans for lifelong dependent care. The article makes no mention, however, of DNA testing for rare disease in the pre-pregnancy stage, when family planning options are more abundant. For many prospective parents, the sense of urgency to pursue such tests at an otherwise exciting time is lacking. Planning for a child with a severe disability is unpleasant to ponder.
The fact is, less than one percent of couples will test “high-risk” for a rare recessive genetic disease. These couples face a 25% chance of having an affected child; hence, “rare.” But if you’re on the other side of those numbers, statistical rarity is irrelevant. For those who would act on the results to pursue alternate routes of family planning—such as IVF with pre-implantation diagnosis, prenatal testing, gamete donation or adoption— it is worth noting that DNA testing can be performed earlier. Where parents would rather use the information to better prepare for a child with special needs, advanced knowledge of potential complications or treatment options is critical.
In the end, my daughter was in fact, “just fine.” I still wonder about her roommate and whether she ever stopped waiting for a diagnosis. Uncertainty in parenthood is a given. But where there is a test that can minimize some of that uncertainty, waiting is somehow far less appealing.
Shivani was born in raised in the suburbs of New York. Her affinity for genetics began in the 7th grade, when her science teacher gave her the litmus test…literally. She completed an undergraduate degree in Biological Sciences from Rutgers University, and a Master of Science from Mount Sinai School of Medicine of NYU. As a board-certified genetic counselor, Shivani has worked in the fields of reproductive, cancer and pediatric genetics at institutions like Mount Sinai and Weill Cornell. She joined Counsyl in its infancy and has relished the chance to bring genetics to the mainstream. Shivani’s letter to the editor was recently published in the New York Times.
March 17, 2021
NAVIGATING YOUR BREAST AND OVARIAN HEALTH IN THE (NEVER-ENDING) ERA OF COVID
It has been almost a year since most of us found ourselves in the completely unchartered territory of “sheltering in…Read more about NAVIGATING YOUR BREAST AND OVARIAN HEALTH IN THE (NEVER-ENDING) ERA OF COVID
February 25, 2021
I Am Glad to Know: The Importance of Carrier Screening Through the Voice of a Carrier
This Sunday, February 28th, is #RareDiseaseDay! To raise awareness and support for the rare disease community, Myriad Women’s Health partnered…Read more about I Am Glad to Know: The Importance of Carrier Screening Through the Voice of a Carrier
December 23, 2020
Myriad’s 7 Greatest Hits in 2020
Before we say goodbye to 2020, we’d like to thank and recognize our partners. Together, we ensure patients have access…Read more about Myriad’s 7 Greatest Hits in 2020